Literature DB >> 1293869

The role of individual human cytochromes P450 in drug metabolism and clinical response.

S Cholerton1, A K Daly, J R Idle.   

Abstract

Recent advances in the study of human cytochromes P450 by protein purification, molecular cloning techniques and analysis of polymorphisms has led to increased understanding of the role of the various forms in the metabolism of clinically important drugs. In particular, the substrate specificity of one form, CYP2D6, is well established. CYP2D6 shows polymorphism, with 5-10% of Caucasians (poor metabolizers) not expressing this enzyme. The molecular basis of this deficiency is now well understood and methods for the detection of poor metabolizers are discussed, as well as the effect of the polymorphism on drug metabolism. Substrate specificities and possible polymorphisms in other cytochromes P450 are also discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1293869     DOI: 10.1016/0165-6147(92)90140-2

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  39 in total

Review 1.  Drug- and non-drug-associated QT interval prolongation.

Authors:  Charlotte van Noord; Mark Eijgelsheim; Bruno H Ch Stricker
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

Review 2.  Pharmacogenomics of CYP3A: considerations for HIV treatment.

Authors:  Sukhwinder S Lakhman; Qing Ma; Gene D Morse
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

Review 3.  Molecular basis of polymorphic drug metabolism.

Authors:  A K Daly
Journal:  J Mol Med (Berl)       Date:  1995-11       Impact factor: 4.599

Review 4.  The role of non-P450 enzymes in drug oxidation.

Authors:  C Beedham
Journal:  Pharm World Sci       Date:  1997-12

5.  The impact of drug metabolizing enzyme polymorphisms on outcomes after antenatal corticosteroid use.

Authors:  David M Haas; Amalia S Lehmann; Todd Skaar; Santosh Philips; Catherine L McCormick; Kyle Beagle; Scott J Hebbring; Jessica Dantzer; Lang Li; Jeesun Jung
Journal:  Am J Obstet Gynecol       Date:  2012-02-28       Impact factor: 8.661

6.  Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic.

Authors:  David M Haas; Sara K Quinney; Jayanti M Clay; Jamie L Renbarger; Mary F Hebert; Shannon Clark; Jason G Umans; Steve N Caritis
Journal:  Am J Perinatol       Date:  2012-08-08       Impact factor: 1.862

Review 7.  Cytochromes P450 and drug resistance.

Authors:  J Doehmer; A R Goeptar; N P Vermeulen
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

8.  Metoprolol alpha-hydroxylation is a poor probe for debrizoquine oxidation (CYP2D6) polymorphism in Jordanians.

Authors:  H F al-Hadidi; Y M Irshaid; N M Rawashdeh
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

9.  Adverse effects of vitamin E by induction of drug metabolism.

Authors:  Regina Brigelius-Flohé
Journal:  Genes Nutr       Date:  2007-10-16       Impact factor: 5.523

Review 10.  Drug-induced QT interval prolongation: mechanisms and clinical management.

Authors:  Senthil Nachimuthu; Manish D Assar; Jeffrey M Schussler
Journal:  Ther Adv Drug Saf       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.